Improving the Use of Allopurinol in Chronic Gout: Monitoring Oxypurinol Levels to Guide Therapy
Authors:
- 1 September 2011
- journal article
- editorial
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 90 (3) , 363-364
Abstract
Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout. New urate-lowering medications are important options; however, these agents should be reserved for patients who do not tolerate or cannot achieve SUA <6 mg/dl on allopurinol. The result of oxypurinol monitoring to guide allopurinol therapy suggests that allopurinol should still be considered first-line ULT for gout.Keywords
This publication has 8 references indexed in Scilit:
- Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate LevelClinical Pharmacology & Therapeutics, 2011
- Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairmentArthritis & Rheumatism, 2011
- New advances in the treatment of gout: review of pegloticaseTherapeutics and Clinical Risk Management, 2010
- The Effect of Serum Urate on Gout Flares and Their Associated CostsJCR: Journal of Clinical Rheumatology, 2009
- Gout Medication Treatment Patterns and Adherence to Standards of Care From a Managed Care PerspectiveMayo Clinic Proceedings, 2006
- Epidemiology of Crystal ArthropathyRheumatic Disease Clinics of North America, 2006
- Serum Urate Levels and Gout FlaresJCR: Journal of Clinical Rheumatology, 2006
- Severe allopurinol toxicityThe American Journal of Medicine, 1984